1. Home
  2. TOPS vs GNPX Comparison

TOPS vs GNPX Comparison

Compare TOPS & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TOP Ships Inc.

TOPS

TOP Ships Inc.

N/A

Current Price

$2.15

Market Cap

2.2M

ML Signal

N/A

Logo Genprex Inc.

GNPX

Genprex Inc.

N/A

Current Price

$1.68

Market Cap

2.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TOPS
GNPX
Founded
2000
2009
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
2.2M
IPO Year
2004
2017

Fundamental Metrics

Financial Performance
Metric
TOPS
GNPX
Price
$2.15
$1.68
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 303.3K
110.6K
Earning Date
09-16-2026
11-13-2026
Dividend Yield
★ 35.44%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.14
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$0.42
52 Week High
$7.40
$9.99

Technical Indicators

Market Signals
Indicator
TOPS
GNPX
Relative Strength Index (RSI) 63.71 31.86
Support Level $0.59 $0.80
Resistance Level $2.31 $2.42
Average True Range (ATR) 0.31 0.19
MACD 0.06 -0.01
Stochastic Oscillator 53.44 2.80

Price Performance

Historical Comparison
TOPS
GNPX

About TOPS TOP Ships Inc.

TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco-tanker vessels, focusing on the transportation of crude oil, petroleum products (both clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements. The company operates in two reportable segments: (i) the tanker segment and (ii) the megayacht segment.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

Share on Social Networks: